Diabetic foot ulcers are common complication of poorly controlled diabetes, forming as a result of skin tissue breaking down and exposing the layers underneath. It is commonly located on the bottom of the foot. The major causes of diabetic ulcers includes , high blood sugar, nerve damage, and irritated or wounded feet.
The global diabetic foot ulcer treatment market is estimated to be valued at US$ 6,411.3 million in 2021 and is expected to exhibit a CAGR of 10.2% during the forecast period (2021-2028).
Figure 1.Global Diabetic Foot Ulcer Treatment Market Share (%) in Terms of Value, By Product, 2021
Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcers is expected to drive the market growth during the forecast period.
Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcers is expected to drive the global diabetic foot ulcer treatment market growth over the forecast period. For instance, according to the American Diabetes Association, in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Moreover, according to the Diabetic Foot Journal, in 2019, around 169,000 individuals had diabetic foot ulcers in the U.K.
|Base Year:||2020||Market Size in 2021:||US$ 6,411.3 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||10.2%||2028 Value Projection:||US$ 12,653.3 Mn|
3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB
|Restraints & Challenges:||
Figure 2.Global Diabetic Foot Ulcer Treatment Market Share (%), , 2021
Availability of explicit dressings for specific type of foot ulcers is expected to drive the market growth during the forecast period.
Availability of explicit dressings for specific type of diabetic is expected to boost the market growth during the forecast period. For instance, hydrocolloid dressings such as DuoDERM or IntraSite hydrocolloid are available for . Such dressings help to maintain moist environment for faster wound healing and allow autolytic debridement. Absorptive dressings including calcium alginates (e.g., Kaltostat and Curasorb) are available for exudative wounds in
Global Diabetic Foot Ulcer Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. For instance, according to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in over 190 million infected individuals worldwide as of July 19, 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players operating in the global diabetic foot ulcer treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Diabetic Foot Ulcer Treatment Market: Restraint
The major factors that are expected to hinder growth of the global diabetic foot ulcer treatment market include high cost of diabetic foot ulcer medication and care. For instance, according to the Therapeutic Advances in Endocrinology and Metabolism 2018, the total medical cost for the management of diabetic foot disease ranges from US$ 9 to US$ 15 billion in the U.S.
Major players operating in the global diabetic foot ulcer treatment market include 3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB.
Diabetic foot ulcer is a common condition in diabetic patients, which may lead to amputation of the leg. People who rely on insulin for the treatment of diabetes are at high risk of developing a foot ulcer. Moreover, people suffering from diabetes-related kidney, eye, and heart disease and obesity can also suffer from diabetic foot ulcers. The risk of the disease is high in those consuming alcohol and tobacco. The common initial symptoms of diabetic foot ulcer include unusual swelling, redness, irritation, and stenches on one or both feet. Diabetic foot ulcer treatment, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy.
Key players operating in the global diabetic foot ulcer treatment market are focusing on adoption of growth strategies such as product launches and regulatory approvals, which are expected to drive the market growth during the forecast period. For instance, in November 2019, Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden-based biopharmaceutical company, received a patent in the U.S. for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers. Moreover, in December 2019, Orpyx Medical Technologies Inc., a medical device company that designs and develops sensory insole systems for the treatment of diabetic foot ulcers, launched Orpyx SI Sensory Insoles with for the prevention of diabetic foot ulcers and neuropathy-related ulcers. Furthermore, in December 2017, SANUWAVE Health Inc., received the US approval for marketing of the Dermapace system, the indicated to treat diabetic foot ulcer.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.